Dr. Gadgeel on Docetaxel Plus Trametinib in KRAS-Mutated Recurrent NSCLC
In this video, Shirish M. Gadgeel, MD, of Rogel Cancer Center, University of Michigan, discusses combo docetaxel/trametinib in G12C or non-G12C KRAS mutation-positive, recurrent NSCLC.
In this video, Shirish M. Gadgeel, MD, of Rogel Cancer Center, University of Michigan, spoke with Cancer Network about the results of a phase II study (abstract 9021), which were presented at ASCO 2019. The trial focused on docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation-positive, recurrent non-small cell lung cancer.
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
